Molecular Insight Pharmaceuticals has completed a phase I dosimetry trial of its oncology molecular radiotherapeutic agent, Azedra (Ultratrace iobenguane I-131 or Ultratrace MIBG), the company announced.
Results from the trial were presented at the European Association of Nuclear Medicine's 2007 meeting in Copenhagen, Denmark. Developed using Molecular Insight's Ultratrace technology, Azedra has a fast-track designation from the U.S. Food and Drug Administration. It is designed to maximize the effectiveness of radiotherapy delivered to neuroendocrine tumors, according to the Cambridge, MA-based firm.
By AuntMinnie.com staff writers
October 18, 2007
Related Reading
Molecular Insight buys manufacturing site, October 3, 2007
Molecular Insight appoints CFO, August 16, 2007
Molecular Insight posts Q2 2007 results, August 13, 2007
Molecular Insight buys Texas radiopharma plant, May 18, 2007
Molecular Insight adds revenues in Q1, May 15, 2007
Copyright © 2007 AuntMinnie.com
